Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Is AUB an opportunity after shares plunge 17%?
stocks
Attractive ASX listed income opportunity
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 11.10 | 0.13% |
| CAC 40 | 8,097.00 | 25.71 | -0.32% |
| DAX 40 | 23,589.44 | 247.35 | -1.04% |
| Dow JONES (US) | 47,289.33 | 427.09 | -0.90% |
| FTSE 100 | 9,702.53 | 17.98 | -0.18% |
| HKSE | 26,032.89 | 0.37 | -0.00% |
| NASDAQ | 23,275.92 | 89.76 | -0.38% |
| Nikkei 225 | 49,303.45 | 0.17 | 0.00% |
| NZX 50 Index | 13,502.77 | 54.28 | 0.40% |
| S&P 500 | 6,812.63 | 36.46 | -0.53% |
| S&P/ASX 200 | 8,579.70 | 14.50 | 0.17% |
| SSE Composite Index | 3,894.29 | 19.71 | -0.50% |